glargine and aspart

PreclinicalSmall molecule

UUniversity of Pennsylvania

glargine and aspart is one of 20 small molecule programs targeting Pilot Study. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pilot StudyWithdrawn

Pilot StudyPreclinical

Withdrawn

Competition

Competitive Landscape

27 competitors in Pilot Study

#DrugCompanyPhaseTrials

Farxiga

AstraZeneca

Approved

1 2

Doptelet

AAkarx

Approved

1 3

Glucophage

EMD Serono

Phase 2

1 4

CC-486

Bristol-Myers Squibb

Phase 2

1 5

Atibuclimab

IImplicit Bioscience

Phase 2

1 6

Rapamycin

MMaastricht Radiation Oncology

Phase 1

1 7

Hytrin

AAbbott

Preclinical

1 8

Reyataz

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 9

Lopinavir/ritonavir

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Preclinical

1 10

Sonovue

BBracco Diagnostics, Inc

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pilot Study1 trial

Pilot Study of Clinician-supported Patient Self-management of Hospital Insulin Therapy

Withdrawn·UUniversity of Pennsylvania·N/A·NCT02144441

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for glargine and aspart. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — glargine and aspart compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for glargine and aspart. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Pennsylvania company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Pennsylvania

glargine and aspart

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pilot Study1 trial

References

Drug Info

Quick Facts

Related News